Kilitch Drugs (India)'s Q4 FY 2025-26 Quarterly Results

Result Summary

• Kilitch Drugs (India) Ltd reported a 62.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 43.2%.
• Its expenses for the quarter were up by 40.5% QoQ and 42.4% YoY.
• The net profit increased 245.2% QoQ and increased 45.6% YoY.
• The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 4.24 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Kilitch Drugs (India) Ltd is a pharmaceutical company that operates in the healthcare and life sciences sector. The company is involved in the manufacturing and marketing of a wide range of pharmaceutical products. These products include formulations and active pharmaceutical ingredients (APIs), which are used in various therapeutic categories. Kilitch Drugs has established itself as a key player within the Indian pharmaceutical industry, focusing on quality and innovation in its product offerings. Currently, detailed information on any recent major developments within the company is not available.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Kilitch Drugs (India) Ltd reported a total income of ₹90.10 crores. This marks a significant increase of 62.8% quarter-over-quarter (QoQ) compared to ₹55.34 crores in the third quarter of fiscal year 2026 (Q3FY26). On a year-over-year (YoY) basis, the total income rose by 43.2% from ₹62.92 crores in the fourth quarter of fiscal year 2025 (Q4FY25). These figures reflect the company's strong revenue generation capabilities during this period.

Profitability

Kilitch Drugs (India) Ltd's profitability showed marked improvement in Q4FY26. The company reported a profit before tax of ₹20.21 crores, a substantial increase of 260.9% QoQ from ₹5.60 crores in Q3FY26 and an increase of 46.0% YoY from ₹13.84 crores in Q4FY25. After accounting for taxes amounting to ₹5.33 crores in Q4FY26, the profit after tax stood at ₹14.88 crores. This represents a QoQ growth of 245.2% from ₹4.31 crores in Q3FY26 and a YoY increase of 45.6% from ₹10.22 crores in Q4FY25. Earnings per share (EPS) for Q4FY26 was ₹4.24, which is a 69.6% increase QoQ from ₹2.50 in Q3FY26 but a decrease of 34.5% YoY from ₹6.47 in Q4FY25.

Operating Metrics

Total expenses for Kilitch Drugs (India) Ltd in Q4FY26 were reported at ₹69.88 crores, reflecting a 40.5% increase QoQ from ₹49.75 crores in Q3FY26 and a 42.4% increase YoY from ₹49.08 crores in Q4FY25. The company's tax expense in Q4FY26 was ₹5.33 crores, which shows a significant increase of 316.4% QoQ from ₹1.28 crores in Q3FY26 and a 46.8% increase YoY from ₹3.63 crores in Q4FY25. This data highlights the various components of operational costs and tax obligations impacting the company's financial performance during the quarter.